Works matching IS 17762596 AND DT 2022 AND VI 17 AND IP 1
Results: 12
Representativeness of Phase III Trial for Osimertinib in Pretreated Advanced EGFR-Mutated Non-small-cell Lung Cancer Patients and Treatment Outcomes in Clinical Practice.
- Published in:
- Targeted Oncology, 2022, v. 17, n. 1, p. 53, doi. 10.1007/s11523-021-00862-x
- By:
- Publication type:
- Article
Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System.
- Published in:
- Targeted Oncology, 2022, v. 17, n. 1, p. 43, doi. 10.1007/s11523-021-00865-8
- By:
- Publication type:
- Article
Correction to: Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies: Their Use and Differential Features.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Correction to: Durvalumab: A Review in Extensive-Stage SCLC.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Concomitant Proton Pump Inhibitors and Outcome of Patients Treated with Nivolumab Alone or Plus Ipilimumab for Advanced Renal Cell Carcinoma.
- Published in:
- Targeted Oncology, 2022, v. 17, n. 1, p. 61, doi. 10.1007/s11523-021-00861-y
- By:
- Publication type:
- Article
A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China.
- Published in:
- Targeted Oncology, 2022, v. 17, n. 1, p. 1, doi. 10.1007/s11523-021-00859-6
- By:
- Publication type:
- Article
Real-World Outcomes Among Crizotinib-Treated Patients with ROS1-Positive Advanced Non-Small-Cell Lung Cancer: A Community Oncology-Based Observational Study.
- Published in:
- Targeted Oncology, 2022, v. 17, n. 1, p. 25, doi. 10.1007/s11523-021-00860-z
- By:
- Publication type:
- Article
MYL-1402O: A Bevacizumab Biosimilar.
- Published in:
- Targeted Oncology, 2022, v. 17, n. 1, p. 85, doi. 10.1007/s11523-021-00858-7
- By:
- Publication type:
- Article
Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies: Their Use and Differential Features.
- Published in:
- Targeted Oncology, 2022, v. 17, n. 1, p. 69, doi. 10.1007/s11523-021-00857-8
- By:
- Publication type:
- Article
Prognostic Differences of RAS Mutations: Results from the South Australian Metastatic Colorectal Registry.
- Published in:
- Targeted Oncology, 2022, v. 17, n. 1, p. 35, doi. 10.1007/s11523-021-00856-9
- By:
- Publication type:
- Article
A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Correction to: Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice